ISSN: 3065-0631

Columbia Journal of Medical Research and Practice

Research Article

MEDICATION INTERVENTIONS FOR AGGRESSIVE BEHAVIORS IN DEMENTIA-RELATED PSYCHOLOGICAL SYMPTOMS

Dr. Fatima Hauwa Bello

Department of Geriatric Psychiatry, University of Ibadan, Ibadan, Nigeria

DOI:10.5281/zenodo.19660966

Abstract

Dementia is a progressive neurodegenerative disorder characterized by cognitive decline, affecting an estimated 55 million people globally, with prevalence projected to rise substantially by 2050. Beyond cognitive impairment, behavioral and psychological symptoms of dementia (BPSD) pose significant challenges in clinical management, with aggression being among the most distressing manifestations. Aggressive behaviors—including verbal outbursts, physical attacks, resistance to care, and socially inappropriate actions—affect 20–30% of individuals with dementia, exacerbating caregiver burden, accelerating functional decline, increasing the likelihood of institutionalization, and inflating healthcare costs. The development of aggression in dementia is multifactorial, arising from neuropathological changes, unmet physical or emotional needs, environmental stressors, and communication barriers. Effective management strategies are essential to mitigate these impacts, with pharmacological interventions playing a central role in controlling aggressive behaviors and improving patient and caregiver outcomes. This review examines current drug-based approaches for aggression in dementia, highlighting evidence-based practices, safety considerations, and clinical challenges.

Keywords: Dementia, Aggression, Behavioral Symptoms, Pharmacological Intervention, Neurodegeneration

Introduction

Dementia is a progressive and irreversible neurodegenerative disorder that significantly impairs cognitive and functional abilities. As one of the most pressing global health concerns, it affects an estimated 55 million individuals worldwide—a number projected to rise to 78 million by 2030 and to 139 million by 2050, according to the World Health Organization. While the hallmark of dementia is cognitive deterioration—including memory loss, language difficulties, and impaired judgment—its behavioral and psychological symptoms often pose even greater challenges in clinical care. Among these, aggression is one of the most troubling and disruptive manifestations, affecting approximately 20–30% of individuals with dementia at some point during the disease course.

Aggression in dementia may manifest in various forms, including verbal outbursts, physical attacks, resistance to care, and inappropriate social behavior. These behaviors are not only distressing for the patient but also lead to increased caregiver burden, faster functional decline, earlier institutionalization, and elevated healthcare costs. The etiology of aggression in dementia is multifactorial, often reflecting complex interactions between neuropathological changes, unmet physical or emotional needs, environmental stressors, and communication barriers.

From a neurobiological perspective, aggression in dementia is associated with structural and functional alterations in key brain regions such as the prefrontal cortex, amygdala, and hippocampus. Dysregulation of

neurotransmitter systems—including dopamine, serotonin, and acetylcholine—has also been implicated. These disturbances may lead to heightened impulsivity, irritability, and reduced capacity for emotional regulation, all of which contribute to aggressive behavior.

Given the complexity of aggression in dementia, its management requires a multifaceted approach. Nonpharmacological interventions—such as environmental modifications, behavioral therapy, and caregiver education—are widely recommended as first-line treatments. These approaches aim to address underlying causes, enhance communication, and reduce triggers. However, when aggression escalates to the point of posing risks to the patient or others, pharmacological interventions are often considered necessary.

Antipsychotic medications—divided into first-generation (typical) and second-generation (atypical) agents—are the most frequently prescribed pharmacological treatments for aggression in dementia. Typical antipsychotics, such as haloperidol, primarily exert their effects through dopamine D2 receptor antagonism. While effective in reducing agitation, their use is limited by a high risk of extrapyramidal symptoms and sedation. Atypical antipsychotics, including risperidone, olanzapine, and quetiapine, target both dopamine and serotonin receptors and are generally preferred due to a more favorable side effect profile.

Despite their widespread use, antipsychotics are associated with substantial risks. Studies have demonstrated increased mortality and cerebrovascular events in elderly patients with dementia treated with these agents. These concerns prompted the U.S. FDA and EMA to issue black box warnings, cautioning against routine antipsychotic use in dementia-related psychosis. Furthermore, antipsychotics may exacerbate cognitive decline and contribute to other complications such as falls, orthostatic hypotension, metabolic disturbances, and prolonged sedation.

Given these risks, current clinical guidelines emphasize nonpharmacological interventions as the preferred initial strategy. Pharmacological treatment, particularly antipsychotics, should be reserved for severe, refractory cases and used at the lowest effective dose for the shortest possible duration. Informed consent, close monitoring, and regular re-evaluation are critical components of ethical prescribing in this vulnerable population.

In addition to antipsychotics, other pharmacological agents have been explored for their potential to manage aggression in dementia. Selective serotonin reuptake inhibitors (SSRIs), such as sertraline and citalopram, have shown promise in reducing aggression with fewer adverse effects compared to antipsychotics. Mood stabilizers like valproate and carbamazepine, and anticonvulsants such as gabapentin, have also been studied, although evidence for their efficacy remains mixed.

Beyond pharmacological solutions, emerging research is exploring novel approaches such as precision medicine, pharmacogenomics, and neuromodulation techniques. Personalized medicine seeks to tailor treatments based on genetic, biological, and clinical profiles, potentially enhancing efficacy and minimizing risks. Additionally, innovations in non-invasive brain stimulation, cannabinoid-based therapies, and anti-inflammatory agents are being investigated for their potential to address neuropsychiatric symptoms of dementia without the burden of traditional antipsychotics.

Ethical considerations play a pivotal role in the management of aggression in dementia. Prescribing decisions must weigh the potential benefits against the considerable risks, always prioritizing patient dignity, autonomy,

and quality of life. Moreover, the perspectives of caregivers—who often bear the brunt of managing aggressive behavior—must be integrated into treatment planning. Shared decision-making, transparent communication, and ongoing support are essential in navigating these complex and emotionally charged situations.

In summary, aggression in dementia is a significant clinical and ethical challenge that requires a nuanced, individualized approach. While antipsychotics may offer symptomatic relief in selected cases, their use must be guided by rigorous evidence, clinical judgment, and ethical principles. This literature review aims to provide a comprehensive understanding of the pharmacological management of aggression in dementia, with a particular focus on the role and risks of antipsychotics. By examining current practices, evaluating emerging alternatives, and highlighting areas for future research, the review seeks to contribute to more informed, compassionate, and effective care for individuals living with dementia.

Pathophysiology of Aggression in Dementia

Introduction

Aggression is a hallmark neuropsychiatric symptom of dementia, falling under the broad spectrum of Behavioural and Psychological Symptoms of Dementia (BPSD). These symptoms, which include agitation, delusions, hallucinations, depression, apathy, and disinhibition, severely compromise quality of life and caregiving environments. Aggression is particularly challenging as it increases caregiver burden, risk of institutionalization, and patient morbidity. Understanding the underlying neurobiological, neurochemical, and anatomical factors responsible for aggression in dementia is essential for developing targeted and effective interventions.

Overview of Dementia and Aggression

Dementia is a clinical syndrome caused by various neurodegenerative and vascular disorders, with Alzheimer's disease (AD), Lewy body dementia (LBD), frontotemporal dementia (FTD), and vascular dementia (VaD) being the most common. Aggression is especially prevalent in AD and FTD. The clinical expression of aggression may vary depending on the type of dementia, severity of disease, environmental stressors, and underlying neuropathology.

Neuroanatomical Basis of Aggression

Serotonin Deficiency

Serotonergic dysfunction is perhaps the most well-established biochemical contributor to aggression. Postmortem studies and cerebrospinal fluid (CSF) analyses show reduced serotonin levels in aggressive dementia patients. SSRIs, which enhance serotonergic tone, have shown modest success in reducing aggression in clinical trials. **Dopaminergic Dysregulation** Hyperdopaminergic activity in mesolimbic circuits and reduced dopaminergic control in prefrontal regions may contribute to heightened agitation and paranoia. Antipsychotics, by acting as dopamine D2 receptor antagonists, aim to mitigate these symptoms but often come with adverse effects.

Dementia Subtypes and Aggression Patterns

Different types of dementia display distinct patterns of aggression based on the regions affected and their neuropathological mechanisms:

Table 2: Dementia Subtypes and Their Link to Aggression

Dementia Type	Key Pathology	Aggression Characteristics
Alzheimer's Disease	Amyloid plaques, neurofibrillary tangles	Late-stage irritability, resistiveness to care
Frontotemporal Dementia (FTD)	Frontal and temporal lobe atrophy	Early-onset impulsive, socially inappropriate aggression
Lewy Body Dementia	α-synuclein inclusions	Hallucination-induced aggression, fluctuating cognition
Vascular Dementia	Cerebrovascular lesions	Abrupt mood shifts, frustration due to cognitive decline

inflammation

Neuro inflammation is increasingly recognized as a central factor in both cognitive decline and behavioural disturbances. Activated microglia release proinflammatory cytokines such as IL1β, TNF-α, and IL-6, which can exacerbate synaptic dysfunction and neuronal death. These inflammatory mediators have been correlated with heightened aggression in animal models and human studies of dementia.

Environmental and Behavioural Modulators

Apart from structural and biochemical changes, environmental and psychosocial factors play a major role in modulating aggression. These include:

- Pain and discomfort
- Poor communication or misunderstanding
- Overstimulation or under-stimulation
- Change in caregivers or routines
- Sensory impairments (e.g., poor vision/hearing)

Summary and Clinical Implications

Aggression in dementia is the result of multifactorial disturbances involving disrupted neural circuits, neurotransmitter imbalances, neuroinflammation, and environmental triggers. A clear understanding of these mechanisms is essential for developing targeted pharmacological and non-pharmacological strategies. The next chapter will explore how current pharmacological approaches— particularly the use of antipsychotics—fit into this complex pathophysiological landscape.

ISSN: 3065-0631

Columbia Journal of Medical Research and Practice

Research Article

Overview and Classification of Antipsychotics

Introduction

Antipsychotics are a cornerstone in managing severe behavioural disturbances in dementia, particularly when non-pharmacological strategies are inadequate. Initially developed for schizophrenia and psychotic disorders, their use has expanded to address symptoms like aggression, agitation, and hallucinations in elderly dementia patients. However, antipsychotics are not without controversy; concerns about safety, tolerability, and regulatory limitations complicate their clinical use. Understanding their classification, mechanisms of action, pharmacological profiles, and suitability in dementia-related aggression is fundamental for optimizing patient outcomes. **Classification of Antipsychotics**

Antipsychotics are broadly classified into two major categories:

Table 3: Classification of Anti psychotics

Class	Examples	Primary Receptor Targets	Key Features
Typical (FirstGeneration)	Haloperidol, Chlorpromazine, Fluphenazine	D2 receptor antagonism	High extrapyramidal side effects (EPS)
Atypical (SecondGeneration)	Risperidone, Olanzapine, Quetiapine, Aripiprazole	D2, 5-HT2A antagonism	Lower EPS risk, higher metabolic side effects

Mechanism of Action

Dopamine Hypothesis

The central pharmacological action of antipsychotics involves dopamine D2 receptor antagonism, which reduces dopaminergic hyperactivity, a factor often associated with agitation and psychosis in dementia. Excess dopamine in mesolimbic pathways is implicated in behavioural symptoms, while blockade in the nigrostriatal tract contributes to extrapyramidal symptoms (EPS).

Serotonin-Dopamine Antagonism (Atypicals) Atypical antipsychotics exhibit dual action on:

- 5-HT2A receptors: Modulate dopamine release in key brain regions
- D2 receptors: Reduce psychotic symptoms without full receptor blockade

- acting injectable antipsychotics (LAIs) are under evaluation for reducing caregiver burden and improving compliance.
- New agents such as pimavanserin (a selective 5-HT2A inverse agonist) are being tested in dementia-related psychosis with reduced risk profiles.

Summary

Antipsychotics are a valuable but risky pharmacological option in managing aggression in dementia. Their use should be informed by a thorough understanding of their classification, mechanism, and side effect profile. Atypical antipsychotics offer a better safety profile compared to typical ones, but none are free from risks—especially in frail, elderly patients. Judicious use, guided by current clinical guidelines and patient-specific factors, is critical.

Efficacy of Antipsychotics in Dementia

Introduction

Aggression and agitation are among the most disruptive behavioural and psychological symptoms of dementia (BPSD), affecting up to 90% of patients during the disease course. The pharmacological management of these symptoms has often relied on antipsychotic medications, primarily due to their dopamineblocking and serotonergic-modulating effects. However, the therapeutic efficacy of antipsychotics in dementia-related aggression remains a topic of ongoing debate. This chapter critically examines clinical evidence from randomized controlled trials, systematic reviews, and meta-analyses to determine the efficacy of both typical and atypical antipsychotics in treating aggression in dementia.

Defining Efficacy in Dementia-Related Aggression

Efficacy in this context is generally measured using standardized behavioural rating scales, such as:

- Neuropsychiatric Inventory (NPI)
- Cohen-Mansfield Agitation Inventory (CMAI)
- Brief Psychiatric Rating Scale (BPRS)
- Clinical Global Impression (CGI) scale

A clinically significant response is often defined as a ≥30% reduction in total aggression/agitation score on these scales.

Evidence from Randomized Controlled Trials (RCTs)

Risperidone

Risperidone has shown the most consistent evidence among atypical antipsychotics in managing aggression. A pivotal double-blind, placebo-controlled study by Katz et al. (1999) demonstrated significant reductions in hostility and aggression in Alzheimer's patients treated with risperidone (1–2 mg/day) compared to placebo.

ISSN: 3065-0631

Columbia Journal of Medical Research and Practice

Research Article

Another trial by De Deyn et al. (1999) involving 345 patients showed that risperidone was effective in reducing aggressive behaviour, with the most notable results at lower doses (0.5–1.0 mg/day). **Olanzapine**

Olanzapine has shown mixed results. In a study by Street et al. (2000), olanzapine (5–10 mg/day) significantly reduced NPI aggression subscale scores compared to placebo. However, it was also associated with increased sedation and weight gain.

Quetiapine

Quetiapine has not consistently demonstrated superiority over placebo in terms of aggression reduction. Tariot et al. (2006) found quetiapine (mean dose 200 mg/day) to be comparable to placebo but better tolerated than risperidone.

Haloperidol

Haloperidol is effective, particularly in acute aggression. A Cochrane review by Lonergan et al. (2002) concluded that haloperidol may be more effective than placebo in short-term use but is limited by severe extrapyramidal side effects.

Figure 3: Summary of Antipsychotic Efficacy Across RCTs

Meta-Analyses and Systematic Reviews

Table 6: Major Meta-Analyses Evaluating Antipsychotic Efficacy in Dementia-Related Aggression

Author/Year	# of Studies	Drugs Evaluated	Key Findings
Schneider et al. (2006)	15 RCTs	Risperidone, Olanzapine, Aripiprazole	Small but statistically significant effect; ↑ mortality risk
Maher et al. (2011)	91 trials	All SGAs	SGAs better than placebo in aggression reduction
Tampi et al. (2016)	23 RCTs	All antipsychotics	Modest efficacy; highest for risperidone and olanzapine
Seitz et al. (2013)	20 studies	Atypical antipsychotics	Efficacy at low doses; adverse events increase with dose

Table 7

Parameter	Typical (e.g., Haloperidol)	Atypical (e.g., Risperidone, Olanzapine)
Efficacy in Aggression	Moderate	High (especially risperidone)
Time to Onset	Rapid (24–72 hrs)	Slower (3–7 days)

ISSN: 3065-0631

Columbia Journal of Medical Research and Practice

Research Article

EPS Risk	High	Low to moderate
Mortality/CVA Risk	High	Moderate to high (dose-dependent)
Cognitive Side Effects	Higher	Lower (except olanzapine)

Placebo Effect and Non-Pharmacological Confounding

Placebo responses in dementia trials are surprisingly high. In some studies, over 30% of placebo-treated patients showed marked reductions in aggression, possibly due to environmental modifications, caregiver attention, and regular assessments.

This underscores the importance of including behavioural and environmental interventions alongside pharmacotherapy. **Gaps in Efficacy Research**

- Underrepresentation of real-world settings (e.g., long-term care facilities)
- Limited head-to-head comparisons of antipsychotics
- Scarce data on minority populations and patients with comorbidities
- Need for longer-term efficacy and safety data

Summary and Clinical Implications Antipsychotics, particularly risperidone and olanzapine, demonstrate modest efficacy in managing aggression in dementia, especially when used for short durations at low doses. However, these benefits must be weighed against substantial risks, including cerebrovascular events and mortality. Clinicians must consider patient-specific factors, coexisting conditions, and non-pharmacological strategies when initiating therapy.

Risks and Adverse Effects of Antipsychotics in Dementia

Introduction

While antipsychotics offer therapeutic benefit in reducing aggression and other neuropsychiatric symptoms in dementia, their use is shadowed by a significant risk profile, particularly in elderly populations. Numerous studies and regulatory authorities have raised concerns regarding their association with increased mortality, cerebrovascular adverse events (CVAE), metabolic complications, extrapyramidal symptoms (EPS), cognitive worsening, and infections. These risks are dose-dependent,

Mortality Risk

One of the most alarming findings is the association of antipsychotics with increased allcause mortality in dementia patients. A 2005 FDA alert based on 17 randomized, placebocontrolled trials noted that atypical antipsychotics are associated with a 1.6- to 1.7fold increase in mortality compared to placebo [1].

Meta-analyses show mortality rates of approximately:

- 4.5% in antipsychotic-treated patients
- 2.6% in placebo groups over 10–12 weeks

Figure 1: Forest plot showing odds ratio for mortality with antipsychotic use in dementia patients across RCTs.

Cerebrovascular Adverse Events (CVAEs)

Antipsychotic use increases the risk of stroke and transient ischemic attacks, particularly with risperidone and olanzapine.

- Risk Ratio: Up to 2.3-fold increase in CVAEs
- Mechanism: Possibly linked to hypotension, arrhythmias, increased platelet aggregation, and endothelial dysfunction

Risperidone is associated with the highest risk, especially in females and those with a history of CVA or atrial fibrillation [2].

Extrapyramidal Symptoms (EPS)

Typical antipsychotics like haloperidol are notorious for EPS, including:

- Parkinsonism
- Akathisia
- Dystonia
- Tardive dyskinesia

These are less common with atypicals but not absent. Risperidone and aripiprazole may still induce EPS, especially at higher doses or in combination with other dopamine antagonists.

Sedation and Cognitive Worsening

Sedation is a frequent and dose-limiting side effect, particularly with quetiapine and olanzapine. Sedation may result in: Reduced mobility

Table 9: Comparison of EPS Risk

Drug	EPS Risk (High to Low)
Haloperidol	Very High
Risperidone	Moderate
Olanzapine	Low
Quetiapine	Very Low

- Increased risk of pressure ulcers
- Daytime drowsiness
- Social withdrawal

Additionally, studies indicate cognitive decline is accelerated in patients on long-term antipsychotic therapy. Cognitive adverse effects may be due to anticholinergic load and dopaminergic suppression [3].

Metabolic Side Effects

Atypical antipsychotics are linked with:

- Weight gain
- Hyper glycaemia
- Dyslipidaemia

ISSN: 3065-0631

Columbia Journal of Medical Research and Practice

Research Article

Olanzapine and clozapine are particularly associated with metabolic syndrome, increasing cardiovascular risk in an already vulnerable population.

Figure 2: Chart showing metabolic side effects incidence with atypical antipsychotics (olanzapine > quetiapine > risperidone > aripiprazole)

Falls, Fractures, and Orthostatic Hypotension

Falls are a leading cause of morbidity in older adults with dementia. Antipsychotics contribute through:

- Sedation
- Orthostatic hypotension
- Impaired coordination

Orthostatic hypotension occurs through α1adrenergic blockade, particularly notable with quetiapine and risperidone.

QT Prolongation and Cardiac Toxicity

Some antipsychotics—especially ziprasidone, haloperidol (IV), and risperidone—prolong the QT interval, potentially leading to torsades de pointes or sudden cardiac death.

Risk is compounded in elderly patients taking other QT-prolonging drugs (e.g., SSRIs, macrolides).

Pneumonia and Infections

Antipsychotic use is linked to a 30–60% increased risk of pneumonia, especially within the first 30 days of initiation [4]. Mechanisms include:

- Sedation and aspiration
- Anticholinergic-induced dry mouth
- Immune modulation

Drug Interactions

Elderly patients with dementia are often on multiple medications. Antipsychotics may interact with:

- SSRIs (CYP2D6 inhibitors) – ↑ Risperidone levels
- Anticholinergics – Cognitive decline, constipation
- Benzodiazepines – Synergistic sedation and falls

Risk Factors for Adverse Events

Table 10: Major Risk Factors Increasing Antipsychotic-Related Adverse Events in Dementia

Risk Factor	Associated Complication
Age > 80	Higher mortality and CVAE risk
History of stroke	Increased risk of recurrent CVA
Atrial fibrillation	CVAE, hypotension
Multiple comorbidities	Increased sedation, QT prolongation
Polypharmacy	Drug interactions
Low BMI	Enhanced drug sensitivity

Strategies to Minimize Risk

1. Risk-Benefit Assessment before prescribing
2. Start low, go slow: Use minimum effective dose
3. Short duration: Reassess within 6–12 weeks
4. Monitor: For EPS, metabolic labs, QT interval
5. Review medications for interactions
6. Deprescribe once symptoms stabilize **Summary**

Antipsychotics present a high-risk intervention for dementia-related aggression. Despite their potential benefits in acute settings, especially with risperidone and olanzapine, their long-term use is associated with serious adverse effects including mortality, stroke, and cognitive decline. A judicious, individualized, and guideline-based approach is essential, favouring the lowest dose for the shortest time, and prioritizing safer alternatives when possible.

Non-Pharmacological
Alternatives and Adjuncts for Managing
Aggression in Dementia

Introduction

The management of aggression and agitation in dementia is complex, requiring a multidimensional and patient-centred approach. Given the considerable risks associated with antipsychotic use—including increased mortality and cerebrovascular events—there has
been a shift toward exploring nonpharmacological interventions as first-line strategies. These interventions not only minimize harm but also often improve patient quality of life, functional ability, and caregiver satisfaction. This chapter examines various nondrug therapies, their evidence base, and how they integrate with or reduce reliance on antipsychotics.

Rationale for Non-Pharmacological
Interventions

Non-pharmacological approaches are recommended as first-line treatment for behavioural and psychological symptoms of dementia (BPSD), including aggression, by several international guidelines (NICE, APA, WHO). Key rationales include:

- High burden of antipsychotic side effects
- Behavioural symptoms often triggered by unmet needs (e.g., pain, boredom, sensory deficits)
- Potential for long-term behavioural improvements
- Focus on holistic, person-centred care

ISSN: 3065-0631

Columbia Journal of Medical Research and Practice

Research Article

Categories of Non-Pharmacological Interventions

Sensory Stimulation Approaches

Music Therapy

Table 11: Classification of Non-Pharmacological Interventions for Aggression in Dementia

Category	Examples	Primary Focus
Sensory Stimulation	Music therapy, aromatherapy, massage, light therapy	Relaxation and emotional regulation
Behavioural Therapy	Cognitive-behavioural therapy (CBT), positive reinforcement	Habit modification, emotional reframing
Cognitive and Reminiscence	Validation therapy, reminiscence therapy, reality orientation	Enhancing identity and social connection
Environmental Modifications	Noise control, furniture layout, lighting adjustment	Reducing triggers and confusion
Physical and Social Activities	Exercise, dance, gardening, pet therapy	Reducing boredom and restlessness
Caregiver Education and Training	Skills training, communication techniques	Prevention and de-escalation of aggression

Music therapy is one of the most evidence-based non-pharmacological approaches in dementia care. It reduces aggression by:

- Stimulating memory and emotions
- Reducing anxiety and boredom
- Enhancing social interaction

A meta-analysis by van der Steen et al. (2018) showed that individualized music therapy reduced aggression scores significantly when implemented 2–3 times per week for 6–12 weeks [1].

Aromatherapy

ISSN: 3065-0631

Columbia Journal of Medical Research and Practice

Research Article

benefits by combining tactile stimulation.



Figure 4: Illustration of how sensory inputs influence mood regulation in dementia patients (music → limbic system activation; aromatherapy → olfactory-limbic link)

Light Therapy

Bright light exposure has shown modest improvements in sleep-wake cycles and aggression, especially in sundowning syndrome.

Cognitive and Psychosocial Therapies

Reminiscence Therapy

This technique encourages patients to discuss past experiences, often facilitated by photographs, music, or family stories. It strengthens personal identity and reduces aggression caused by confusion or fear.

Instead of correcting delusional beliefs, validation therapy encourages empathetic engagement, reducing conflict and frustration.

Reality Orientation

This approach reorients the patient to time, place, and person, but must be used carefully— especially in late-stage dementia, where it may cause distress.

Environmental Modifications

Behavioural symptoms in dementia are often a response to environmental stressors. Simple changes can substantially reduce aggression.

ISSN: 3065-0631

Columbia Journal of Medical Research and Practice

Research Article

Validation Therapy

Table 12: Environmental Triggers and Mitigations

Trigger	Mitigation Strategy
Loud noises	Noise-reducing flooring, soft music
Clutter or complex spaces	Clear signage, color-contrast doors

Lavender and lemon balm essential oils are used in controlled trials to reduce agitation. Aromatherapy massage shows even greater

Poor lighting	Consistent circadian lighting systems
Lack of routine	Scheduled meals, activities, rest periods

Physical and Social Activity-Based Therapies

- Exercise programs (e.g., walking, Tai Chi) improve mood and reduce agitation
- Animal-assisted therapy (e.g., petting dogs) provides comfort and engagement
- Art and gardening allow creative expression, reducing boredom and behavioural outbursts **Caregiver Training and Support**

Aggression often stems from communication mismatches. Caregiver education improves recognition of triggers and de-escalation skills.

Key strategies taught:

- Use of calm, non-threatening voice
- Avoid confrontation or correcting delusions

- Distraction and redirection techniques
- Managing personal stress levels

Programs like the DICE (Describe, Investigate,
Create, Evaluate) approach and the ABC (Antecedent-Behaviour-Consequence) framework have been validated for caregiverguided behaviour management. **Technology-Assisted Interventions**

- Telepresence robots and video-call tools reduce isolation-related aggression
- Motion-sensing alarms and fall detectors improve safety

ISSN: 3065-0631

Columbia Journal of Medical Research and Practice

Research Article

- Digital reminiscence tools (e.g., touchscreen tablets) help reconnect patients with memories



Figure 5: Diagram showing technology integration in home-based dementia care (wearables, apps, teleconsultation)

Comparative Efficacy with Pharmacological Treatments

Table 13: Efficacy of non-pharmacological vs Pharmacological Approaches

Outcome	Antipsychotics	Non-Pharmacological Interventions
Aggression Reduction	Moderate (short-term)	Moderate to high (long-term, individualized)
Side Effects	High	Minimal
Caregiver Satisfaction	Low	High

ISSN: 3065-0631

Columbia Journal of Medical Research and Practice

Research Article

Challenges in Implementation

- Requires trained staff and consistent resources
- Caregivers may be unaware or sceptical
- Lack of standardized protocols across institutions
- Shortage of funding for art/music therapists

Integration with Pharmacological Management

A blended model combining low-dose antipsychotics and individualized nonpharmacological strategies shows promise:

- Start with behavioural interventions
- Introduce medications if symptoms persist or pose danger
- Taper drugs as soon as possible while sustaining non-drug methods

Summary and Clinical Recommendations

Non-pharmacological interventions are first-line and essential in managing aggression in dementia. Music therapy, caregiver training, environmental changes, and structured activities are supported by a growing body of evidence and are generally safe. Successful implementation requires interdisciplinary collaboration, staff training, and system-level support.

Chapter 7: Ethical and Legal Considerations in the use of Antipsychotics for Dementia

Introduction

The use of antipsychotic medications in the management of dementia-related aggression presents profound ethical and legal dilemmas. These challenges stem from the delicate balance between alleviating suffering and preserving autonomy, preventing harm and avoiding overmedicalization, and the obligation to act in the best interest of a cognitively impaired individual. Inappropriate or prolonged use of antipsychotics in dementia patients can constitute a breach of ethical standards and may violate legal safeguards intended to protect vulnerable populations. This chapter explores the ethical frameworks and legal contexts relevant to antipsychotic use in dementia, emphasizing informed consent, human rights, professional accountability, and policy-level implications.

Ethical Foundations in Geriatric Psychopharmacology

Mortality Risk	Increased	None
Time to Onset	Fast (1–2 weeks)	Slower (2–4 weeks)

Ethics in dementia care is grounded in the four core principles of biomedical ethics:

1. Autonomy – respecting the individual's right to make informed choices
2. Beneficence – promoting the patient's welfare
3. Non-maleficence – avoiding harm
4. Justice – ensuring fair access and equitable treatment

The clinical decision to initiate an antipsychotic must weigh these principles, recognizing that patients with dementia often have diminished capacity to make autonomous decisions. This creates the need for surrogate decision-makers and raises concerns regarding coercion, consent validity, and informed risk disclosure.

Informed Consent in Dementia Treatment

Obtaining valid informed consent is both an ethical necessity and a legal requirement. However, dementia complicates this process due to cognitive impairment that affects memory, judgment, and understanding.

When a patient lacks decision-making capacity, healthcare providers must:

- Conduct a formal capacity assessment
- Involve a legally authorized representative or next-of-kin
- Provide information in an understandable, compassionate manner
- Document the decision-making process thoroughly

If antipsychotics are initiated, consent must include:

- The reason for use (e.g., risk of harm, distress)
- Expected benefits and alternatives
- Potential adverse effects, including mortality and stroke risk
- Planned duration and monitoring strategy

Failure to secure informed consent or document capacity may expose clinicians and institutions to legal liability and professional censure. **Autonomy vs. Safety: The Ethical Dilemma**

Clinicians often face a conflict between respecting a patient's autonomy and ensuring their safety. For example, an agitated patient with dementia may resist treatment or refuse medication. Covert administration, physical restraint, or forced treatment may follow — all of which are ethically controversial.

The least restrictive alternative principle should guide all decisions. Ethical practice requires that:

- The patient's preferences, history, and values be considered
- Non-pharmacological alternatives be tried and documented
- The goals of care be clarified (e.g., comfort vs. behavioural control)

The use of antipsychotics for staff convenience, institutional routine, or behavioural control without documented clinical justification is considered chemical restraint, raising serious ethical and legal concerns.

Chemical Restraint: Definition and Implications

Chemical restraint refers to the use of medication to control behavior not justified by a medical diagnosis or symptom management but rather to manage institutional workflow or staff convenience. This practice is ethically indefensible and often illegal under patient rights laws.

Regulatory agencies in many countries, including India, the UK, Canada, and the USA, have emphasized that antipsychotics should not be used routinely for agitation or aggression and must be time-limited and clearly justified.

Nursing homes and long-term care facilities have been subject to litigation and regulatory penalties for failing to meet consent and documentation standards regarding antipsychotic use.

Human Rights and Dignity in Dementia Care

International conventions, such as the UN Convention on the Rights of Persons with Disabilities (CRPD), stress the importance of respecting the dignity, autonomy, and equality of persons with cognitive impairment. The indiscriminate use of psychotropics can be viewed as a violation of human rights when it:

- Deprives individuals of agency
- Is used to suppress behavior that could be addressed with empathy and engagement
- Is applied uniformly without patient-specific rationale

Preserving dignity in care means treating patients as persons, not problems. This calls for empathetic communication, personalized care, and therapeutic rather than disciplinary intentions.

Legal Frameworks Governing Antipsychotic Use in Dementia

Across jurisdictions, several laws govern medical treatment of individuals with impaired capacity. These include:

- Mental Healthcare Act (2017, India): Mandates informed consent, respect for autonomy, and periodic review of treatment for those with mental illness.
- The Mental Capacity Act (2005, UK):

Provides a framework for assessing capacity and supports decisions made in the individual's best interests.

- The Americans with Disabilities Act (ADA) and Patient Self-Determination Act (PSDA) (USA): Emphasize autonomy and equal treatment.

Under these laws:

- Inappropriate use of antipsychotics may qualify as neglect or abuse
- Facilities may face legal action for failure to safeguard residents
- Documentation, oversight, and review of antipsychotic use are legally mandated

Professional Guidelines and Regulatory Oversight

Medical associations and geriatric societies worldwide have issued practice guidelines to ensure ethical prescribing:

- The American Geriatrics Society Beers Criteria (2023) classifies antipsychotics as potentially inappropriate in older adults with dementia unless non-pharmacological interventions have failed.
- The National Institute for Health and Care Excellence (NICE) in the UK advises against routine antipsychotic use and recommends a stepwise approach.
- In India, clinical guidelines from the Indian Psychiatric Society (IPS) urge careful documentation, informed consent, and timelimited trials.

Healthcare providers are ethically obligated to adhere to these standards to protect patient welfare and ensure legal compliance.

ISSN: 3065-0631

Columbia Journal of Medical Research and Practice

Research Article

The Role of Families and Surrogate DecisionMakers

Family members often serve as surrogate decision-makers, especially when patients lack capacity. Ethical tensions may arise when family wishes conflict with clinical judgment or institutional policies. A family member may demand medications to calm a relative or oppose antipsychotic use entirely.

Clinicians must:

- Communicate risks and benefits transparently
- Respect cultural values and emotions
- Clarify roles and limitations of surrogate decision-makers
- Strive for consensus through shared decision-making

Surrogates must act in accordance with the patient's known or presumed preferences (substituted judgment) or, failing that, in the patient's best interest.

Ethical Use in Emergency Situations

In extreme cases—such as when a patient becomes physically violent—emergency administration of antipsychotics may be ethically permissible without prior consent, under the doctrine of implied consent for lifesaving intervention. However, such interventions must be:

- Immediately necessary
- Time-limited
- Subject to post-hoc justification and documentation
- Reported to family and legal authorities as required

Frequent reliance on emergencies to justify antipsychotic use signals poor care planning and warrants review.

Ethical Implications of Research in Dementia Patients

Clinical research on antipsychotics in dementia also raises ethical concerns, such as:

- Enrolling patients with impaired consent capacity
- Withholding treatment from placebo groups
- Inadequate representation of non-Western populations • Long-term safety monitoring Ethical research must include:
- Ethics committee approval
- Surrogate consent protocols
- Safety monitoring boards
- Transparent risk-benefit disclosures

Institutional Responsibility and Ethical Climate

Institutions such as hospitals, nursing homes, and care facilities are ethically responsible for fostering a culture of ethical care. This includes: • Training staff in dementia-sensitive care

- Monitoring and auditing psychotropic prescriptions
- Providing access to behavioural specialists
- Encouraging ethical reflection and interdisciplinary consultation

Administrators must ensure that cost-efficiency or staffing limitations do not compromise ethical patient care.

Summary and Clinical Implications

Antipsychotic use in dementia demands a careful balance between ethical obligation, legal standards, and compassionate care. Clinicians must prioritize patient dignity, informed consent, and non-pharmacological alternatives. Ethical practice requires transparency, vigilance, and patient-centered care tailored to each individual's needs, preferences, and rights. Institutions and policymakers must support systems that promote ethical decision-making and reduce unnecessary reliance on high-risk medications.

Future Directions and Recommendations in Managing Dementia-Related Aggression

Introduction

Aggression in dementia is a multifaceted neuropsychiatric challenge that poses significant burdens on patients, caregivers, and healthcare systems. Despite the current reliance on antipsychotics, the risks associated with these medications underscore the need for safer, more effective, and individualized interventions. Future directions in dementia care must be interdisciplinary, combining innovations in pharmacology, technology, psychosocial therapy, and policy frameworks. This chapter discusses emerging therapies, research gaps, policy reforms, and practical recommendations for improving the management of aggression in dementia.

Limitations of Current Approaches

Current strategies, particularly the use of conventional antipsychotics, are often:

- Symptom-targeted rather than diseasemodifying
- Associated with high morbidity and mortality
- Poorly individualized
- Under-regulated in some long-term care environments

Emerging Pharmacological Alternatives

Novel Antipsychotics with Improved Safety Profiles

Newer agents such as pimavanserin and brexpiprazole offer hope for reduced adverse effect profiles.

- Pimavanserin is a selective 5-HT2A inverse agonist approved for Parkinson's disease psychosis and being explored for Alzheimer's-related psychosis. It lacks dopaminergic activity, reducing EPS and metabolic risks [1].
- Brexpiprazole shows reduced side effects and better tolerability in older populations. It's under evaluation in multiple Phase III trials for dementia-related agitation.

Table 14: Comparison of Emerging vs Traditional Antipsychotics

Drug	Mechanism	EPS Risk	Sedation	FDA Status
Haloperidol	D2 antagonist	High	Moderate	Approved (non-specific)
Risperidone	D2/5HT2 antagonist	Moderate	Moderate	Approved (short-term)

ISSN: 3065-0631

Columbia Journal of Medical Research and Practice

Research Article

Pimavanserin	5HT2A inverse agonist	Minimal	Low	Investigational in dementia
Brexpiprazole	Partial D2/5HT1A agonist	Low	Low	Phase III trials ongoing

Anti-inflammatory and Neuroprotective Agents Emerging evidence suggests that neuroinflammation may contribute to aggression and agitation in dementia. Anti-inflammatory agents such as:

- Minocycline
- TNF-α inhibitors
- COX-2 inhibitors (celecoxib)

Figure 5: Schematic of neuro inflammation-induced behavioural dysregulation in dementia and potential anti-inflammatory targets.



Cannabinoids and Serotonergic Modulators

- Dronabinol and other cannabinoids have shown mild to moderate benefits in smallscale studies.
- Serotonergic modulators such as SSRIs (e.g., citalopram) are being repurposed for aggression control, with better tolerability.

Personalized and Precision Medicine Approaches

Future treatment models will likely shift from "one-size-fits-all" pharmacotherapy to biomarker-guided, individualized care based on:

- Genetic profiles (e.g., APOE4, COMT polymorphisms)
- Neuroimaging markers of aggression
- Inflammatory biomarkers

Artificial intelligence (AI) and machine learning can aid in predictive modelling and stratifying risk of aggression and drug response.

Advancements in Non-Pharmacological Interventions

Non-pharmacological approaches are gaining technological and scientific refinement:

- Virtual reality (VR) therapy to provide immersive, calming environments
- AI-driven music therapy tailored to mood and behaviour patterns
- Robotic pets for behavioural engagement and calming
- Telemedicine for early identification and remote intervention

Integrated and Multidisciplinary Care Models

Future dementia care must be grounded in:

- Geriatric psychiatry
- Neurology
- Social work
- Nursing and caregiver training

Models such as Collaborative Care for Older Adults with Dementia (CCOAD) and DICE (Describe-Investigate-Create-Evaluate) are being expanded and evaluated for broader implementation. These models promote:

- Shared decision-making
- Comprehensive behavioural assessment
- Ethical prescribing and deprescribing practices

Health Policy and System-Level Reforms

To promote safer dementia care, governments and institutions should implement:

- Strict antipsychotic use regulations
- Mandatory non-pharmacological trials before prescribing
- Centralized monitoring registries for psychotropic use in dementia
- Reimbursement incentives for non-drug therapies
- Standardized caregiver education modules

The CMS (Centres for Medicare & Medicaid Services) in the USA has successfully reduced inappropriate antipsychotic use by over 30% through the National Partnership to Improve Dementia Care

Global Perspectives and Disparities

The future must also address inequities in dementia care:

- Low- and middle-income countries (LMICs) often lack access to behavioural therapies and face medication overuse
- Cultural beliefs may influence how aggression is interpreted and treated
- International organizations such as WHO must develop context-sensitive protocols and capacity-building strategies

Global collaboration through data sharing, openaccess training, and standardized care templates will be essential for equity in dementia aggression management.

Research Gaps and Opportunities

Despite progress, critical research gaps remain:

- Long-term safety and efficacy of new drugs
- Mechanisms linking neurodegeneration and aggression
- Ethical frameworks for AI-driven behavioural prediction
- Cost-effectiveness of combined therapy models

Future clinical trials should:

- Use diverse populations
- Incorporate caregiver burden metrics
- Include real-world implementation strategies

Practical Recommendations for Clinicians

1. Prioritize non-pharmacological strategies in all care plans.
2. If antipsychotics are required, use the lowest effective dose and regularly reassess.
3. Monitor for adverse effects and consider early deprescribing.
4. Advocate for caregiver support, including training and respite care.
5. Document behaviour patterns clearly before initiating medications.
6. Encourage use of technology-assisted interventions where available.
7. Collaborate in multidisciplinary teams for holistic patient assessment.

Conclusion

Managing aggression in dementia requires a paradigm shift—from reactive, risk-prone pharmacotherapy to proactive, preventive, and personalized care. The future lies in integrating safer pharmacological agents, advanced nondrug interventions, ethical practice, and systemlevel reforms. Collaboration between clinicians, researchers, caregivers, and policymakers will be the cornerstone of progress. As the global burden of dementia grows, so too must our commitment to compassionate, evidence-based, and patient-centered approaches to behavioural management.

ISSN: 3065-0631

Columbia Journal of Medical Research and Practice

Research Article

Annexure

Term	Definition
Aggression in Dementia	Verbal or physical hostility or resistance observed in people with dementia.
Antipsychotics	A class of drugs used to manage psychosis, agitation, and aggression.
Atypical Antipsychotics	Newer generation antipsychotics with fewer extrapyramidal side effects.
BPSD	Behavioural and Psychological Symptoms of Dementia, includes aggression, etc.
D2 Receptor	Dopamine receptor type 2; target of many antipsychotics.
Chemical Restraint	Use of drugs to restrict a person's freedom without medical justification.
Neuroinflammation	Inflammatory response in the brain, often associated with neurodegeneration.
Informed Consent	Voluntary agreement to treatment after being informed of its risks/benefits.
Non-Pharmacological Care	Behavioural and environmental strategies to manage symptoms without medication.
Deprescribing	Systematic process of tapering or stopping medications that may be harmful.

Reference

World Health Organization. (2023). Dementia. https://www.who.int/news-room/fact-sheets/detail/dementia

Livingston, G., Huntley, J., Sommerlad, A., Ames, D., Ballard, C., Banerjee, S., et al. (2020). Dementia prevention, intervention, and care: 2020 report of the Lancet Commission.

Cummings, J. L., Mega, M., Gray, K., Rosenberg-Thompson, S., Carusi, D. A., & Gornbein, J.. (1994). The Neuropsychiatric Inventory: Comprehensive assessment of psychopathology in dementia. Neurology, 44(12), 2308–2314. https://doi.org/10.1212/WNL.44.12.2308

Ballard, C., Corbett, A., Chitramohan, R., & Aarsland, D.. (2009). Management of agitation and aggression associated with Alzheimer's disease. Nature Reviews Neurology, 5(5), 245–255. https://doi.org/10.1038/nrneurol.2009.39

Kales, H. C., Gitlin, L. N., & Lyketsos, C. G.. (2015). Assessment and management of behavioral and psychological symptoms of dementia. BMJ, 350, h369. https://doi.org/10.1136/bmj.h369

Tampi, R. R., Tampi, D. J., Balachandran, S., & Srinivasan, S.. (2016). Antipsychotic use in dementia: A systematic review of benefits and risks.

Schneider, L. S., Dagerman, K. S., & Insel, P.. (2005). Risk of death with atypical antipsychotic drug treatment for dementia.

Porsteinsson, A. P., Drye, L. T., Pollock, B. G., et al. (2014). Effect of citalopram on agitation in Alzheimer disease: The CitAD randomized clinical trial

Maher, A. R., Maglione, M., Bagley, S., et al. (2011). Efficacy and comparative effectiveness of atypical antipsychotic medications for off-label uses in adults.

Seitz, D. P., Adunuri, N., Gill, S. S., Rochon, P. A., & Herrmann, N.. (2011). Antidepressants for agitation and psychosis in dementia. Cochrane Database of Systematic Reviews, 2011(2), CD008191.

Herrmann, N., & Lanctôt, K. L.. (2007). Pharmacologic management of neuropsychiatric symptoms of Alzheimer disease.

Aarsland, D., Ballard, C., & Halliday, G.. (2004). Are Parkinson's disease patients predisposed to dementia? Nature Reviews Neurology, 3(1), 14–20.

Lyketsos, C. G., Carrillo, M. C., Ryan, J. M., et al. (2011). Neuropsychiatric symptoms in Alzheimer's disease. Alzheimer's & Dementia, 7(5), 532–539

Sink, K. M., Holden, K. F., & Yaffe, K.. (2005). Pharmacological treatment of neuropsychiatric symptoms of dementia: A review of the evidence. JAMA, 293(5), 596–608.

Gitlin, L. N., Kales, H. C., & Lyketsos, C. G.. (2012). Managing behavioral symptoms in dementia using nonpharmacologic approaches.

De Deyn, P. P., Katz, I. R., Brodaty, H., et al. (2005). Management of agitation, aggression, and psychosis associated with dementia.

Sultzer DL, Melrose RJ, Mahler ME, Mandelkern MA. The neural correlates of aggression in Alzheimer's disease: An FDGPET study.

Seeman P. Atypical antipsychotics: Mechanism of action. Can J Psychiatry. 2002;47(1):27–38.